AzTrials
AzTrials

Breast CancerPhase 2NCT01603303

Preventing Sexual Dysfunction With Aromatase Inhibitors

A Phase 2 study testing Questionnaires, Education Materials and Luvena in people with Breast Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in menopause and who had breast cancer that was sensitive to the hormone estrogen. Read more about this study

Who is it for?
Ages 18 years and older, women only
Conditions the study is for
Breast Cancer
What is being tested?
Questionnaires, Education Materials and Luvena
Could I receive a placebo?
No, everyone receives an active treatment
How many people
187 participants
Where
1 siteUnited States
Study dates
5 Dec 2012to 11 Aug 2017
Phase
Phase 2
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • Women only
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Diagnosis of Stage 0 to III breast cancer
  • Age over 18 years
  • Began adjuvant therapy with an aromatase inhibitor 12 to 18 months before survey sent out (Benchmark Survey only)
  • Was prescribed adjuvant therapy with an AI (prior chemotherapy or tamoxifen OK) in past 2 to 4 weeks (Randomized Trial only)
  • Had sexual activity at least once in past 12 months (Randomized Trial Study only)
  • Has been in a stable sexual relationship of at least 6 months' duration (Randomized Trial study only)

Who cannot join

  • Women using systemic or vaginal estrogen, testosterone, or dehydroepiandrosterone (DHEA) during the Randomized Trial study will be excluded
  • Women using systemic or vaginal estrogen, testosterone, or dehydroepiandrosterone (DHEA) in the 12 months preceding the Benchmark Survey Study will be excluded
  • Has distant metastases
  • Cannot read or speak English well enough to understand materials and complete questionnaires
  • No access to the internet in a private location

Trial locations and contacts

1 site in 1 country.

United States1 site
  • University of Texas MD Anderson Cancer Center

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Preventing Sexual Dysfunction in Women on Aromatase Inhibitors

Aromatase inhibitors (AIs) are used to try to stop breast cancer from forming or returning after treatment in women who are in menopause and who had breast cancer that was sensitive to the hormone estrogen.

The goal of this study is to learn if it is possible to prevent some AI side effects, particularly problems with vaginal dryness and pain during sexual activity. Researchers also want to compare 2 new vaginal moisturizers to see if using them regularly helps women avoid vaginal dryness. Researchers want to see if preventing these side effects will decrease the number of women who stop taking AIs due to the side effects they cause.

Read the detailed description

If you agree to take part in this study, you will be randomly assigned (as in a roll of dice) to 1 of 2 study groups. You will have a 1 in 3 chance of being assigned to Group 1 and a 2 out of 3 chance of being assigned to Group 2.

All women enrolled in this study:

  • You will complete a set of 8 or 9 brief questionnaires at the start of the study and 6 and 12 months afterwards. The questionnaires should take about 45 to 50 minutes to fill out each time. The questionnaires will be mailed to you with a postage paid return envelope. They include questions about your background and medical history, any symptoms that you may have while taking AIs such as hot flashes, muscle pain, and stiffness. There are also questions about how much exercise you are getting, sexual function and satisfaction, your satisfaction with the treatment you are receiving as part of this study, and if you are continuing to take your AI medication and how often you are taking it. If the study staff does not receive your questionnaires within 2 weeks of mailing them, you will receive reminder phone calls once a week for up to 3 weeks unless you tell the study staff that you are leaving the study. If you do not contact the study staff or you do not mail in your questionnaires after 6 weeks, you will no longer be a part of the study.
  • Along with your questionnaires, you will also be mailed a kit approved by the Food and Drug Administration (FDA) to test your vaginal pH at home and will be provided a postage paid return envelope to mail it back to the study doctor. The kit includes a small plastic stick that you put into your vagina for a moment to test your vaginal fluid. The end of the stick turns different colors, depending on the pH in your vagina. The vagina becomes less acidic after menopause, which may increase the risk of vaginal infections. Sometimes vaginal moisturizers can correct this problem by restoring a pH similar to what it was before menopause.
  • You will also receive a detailed written handout about ways to keep your bones stronger during treatment with AIs and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.

Group 2 women only:

  • You will be given a password to use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer (https://www.tendrilssexandcancer.com/) before, during and after treatment with AIs. You will also be given a printed guide for the website with a timeline for when you should read certain sections and suggestions for trying some of the "exercises" to improve sexual communication, increase affection, and prevent vaginal dryness.
  • A counselor will also schedule times to call you for up to 30 minutes during Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24 of the study to ask how you are doing, if you have been able to avoid side effects from the AIs, and if you need any help using the information in your handout or the website. About 1 of 5 counseling phone calls will be audio-recorded so that researchers can make sure the counselor is covering the topics scheduled for each session. These recordings will usually only be heard by the counselor, the Study Chair, and another MD Anderson faculty member (Andrea Bradford, PhD) who will help with supervising and rating the counselor. Once a tape has been rated (usually within one month of the counseling session), it will be erased. The tape may also be reviewed by other health authorities or the Institutional Review Board (IRB) of MD Anderson to check that the research is being done safely and correctly. If either of these 2 groups review the tapes, the will be destroyed right after they are reviewed. Tapes will only be labelled by your study number, but the counselor may call you by name during the session. All information will be held in strict confidentiality by research staff.
  • You will be randomly assigned (as in the toss of a coin) to get a 6-month supply of 1 of 2 vaginal moisturizers (Luvena or Hyalo-Gyn) to use 2 or 3 times a week. Researchers want to know if one works better than the other for women on AIs.
  • You will be given a 6-month supply of a water-based vaginal lubricant to use during sexual activity.
  • You will also be given a vaginal dilator, which is used to help women to relax their pelvic floor muscles and to increase blood flow into the vaginal walls.
  • All of the materials that you need for the study, including handouts, instructions on using the web site, instructions on using the vaginal moisturizer, vaginal lubricant, and vaginal dilator, as well as the supply of those products, will be mailed to you in a study kit as soon as you complete your baseline questionnaires.

All of your questionnaires and other study records will be identified only with a study number and will not include your name, address, or MD Anderson patient number. A list linking your study number to your identity will be kept either in a locked file cabinet or encrypted on a secure computer. Only the study chair and research staff will be able to see the list. Once all data has been analyzed (May 2015 is the estimated date of completion), these lists will be destroyed. Questionnaires or computer files that identify data only by study number may be kept for up to 10 years to satisfy government rules for research.

Length of Study:

Your active study participation will be over after you complete the questionnaires at 12 months.

Other Information:

You are not required to use the vaginal dilator, the moisturizer, or the lubricant in order to take part in this study, but you will be asked if these products were helpful to you.

This is an investigational study.

Up to 168 women will take part in this study. All will be enrolled at MD Anderson Cancer Center or at MD Anderson Cooper Cancer Center.

Conditions
Breast Cancer
Being tested
Questionnaires, Education Materials, Luvena, Hyalo-Gyn, Vaginal Lubricant
Keywords
Breast Cancer, Localized breast cancer, Postmenopausal women, Aromatase inhibitor, AI, Questionnaires, Surveys, Luvena, Internet based website, Phone counseling, Water-based vaginal lubricant, Hyalo-Gyn
Medical subject headings
Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • QuestionnairesBehavioural

    Also called Surveys

    Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.

  • Education MaterialsOther

    Also called Pamphlets

    Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.

  • LuvenaOther

    Use vaginally 2 or 3 times a week.

  • Hyalo-GynOther

    Use vaginally 2 - 3 times a week.

  • Vaginal LubricantOther

    Water-based vaginal lubricant used during sexual activity.

  • Interactive Internet-Based WebsiteBehavioural

    Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.

  • Telephone Counseling.Behavioural

    Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.

Study groups in NCT01603303
Study groupRoleWhat they receive
Usual Care + Education MaterialsOtherCompletion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Water-based vaginal lubricant used during sexual activity.
Receives: Behavioral: Questionnaires; Other: Education Materials
Luvena GroupExperimentalLuvena used vaginally 2 or 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
Receives: Behavioral: Questionnaires; Other: Education Materials; Other: Luvena; Other: Vaginal Lubricant; Behavioral: Interactive Internet-Based Website; Behavioral: Telephone Counseling.
Hyalo-Gyn GroupExperimentalHyalo-Gyn used vaginally 2 - 3 times a week. Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time. Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes. Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs. Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
Receives: Behavioral: Questionnaires; Other: Education Materials; Other: Hyalo-Gyn; Other: Vaginal Lubricant; Behavioral: Interactive Internet-Based Website; Behavioral: Telephone Counseling.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Sexual Dysfunction Rate Reduction

    The primary outcome measure will be the total score from the Female Sexual Function Index (FSFI), which is calculated according to a standard scoring algorithm and has a well-validated cut-off score of 26.55 or below indicating sexual dysfunction. FSFI subscale scores will also be calculated and analyzed.

    Measured: 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 May 2012 (estimated)
  2. Study start5 Dec 2012
  3. Primary completion11 Aug 2017
  4. Study completion11 Aug 2017

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
187 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01603303
Sponsor's protocol ID
2012-0125
Other IDs
NCI-2014-02451
Status last verified
Aug 2017
First submitted
17 May 2012
Last updated
18 Aug 2017
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A Phase 2 study testing Questionnaires, Education Materials and Luvena in people with Breast Cancer, run by M.D. Anderson Cancer Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 18 Aug 2017. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Sexual Dysfunction Rate Reduction (time frame: 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2017.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in